OTR3 is a biotech company and a gem of French innovation revolutionizing tissue regeneration. Historically, beyond cosmetics, OTR3 has been a company developing medical devices around tissue regeneration and matrix therapies to improve the lives of patients suffering from dermatological or neurological diseases.
Founded by Jean-Pierre Caruelle and Denis Barritault, Professor Emeritus at the Université Paris-Est Créteil, and born out of their long-term medical and industrial vision, OTR3 invented the regenerating agents known as RGTA® or ReGeneraTing Agents. Committed to science and innovation, the team DNA is to build the future of regenerative medicine in its laboratories, in France, where each product is developed according to proven scientific rigor.
“We are driven by one conviction: the only scientific research that guides us and matters to us is the one which brings tangible benefits to society.” Denis Barritault.
This cutting-edge RGTA® (ReGeneraTing Agent) technology, with its triple effect - Replacement, Regeneration, Repair -, is pioneering a new era: it marks the transition from wound dressing to tissue regeneration. As such, RGTA® technology is at the heart of a revolution in regenerative medicine.
Based on decades of biomedical research, this innovative technology uses biomimetics of heparan sulfate, a natural component of the extracellular matrix (ECM) that plays a key role in the tissue regeneration process.
Therefore, OTR3’s vision goes beyond symptomatic treatment.
Its ambition is to propose a universal RGENtec® response to meet all the needs of the human body. So, OTR3 dreams of a world where tissue regeneration is not an utopia, but a reality which is accessible to as many people as possible.
An obsession that guides us every day: transforming our knowledge of RGTA® into effective, safe, and widely adopted RGENtec® solutions.
“Every day, the human body renews around 20 billion cells... So, we are at the beginning of a fascinating story that lies at the heart of the laws of biology.” Denis Barritault.
Optimising natural regeneration to rebuild damaged tissue and preserve human capital is the passion of OTR3, and this is the main objective of pro-regenerating agents. This passion fuels a daily quest: to restore the body’s innate ability to heal itself fully.